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        Mast cells have crucial functions in innate im-
munity. A protective role of mast cells is evident 
in mast cell  –  defi  cient mice that are unprotected 
from acute bacterial peritoneal infection and 
subsequent sepsis (  1, 2  ). Although this protec-
tion has largely been attributed to rapid release 
of mast cell  –  derived TNF, other mechanisms 
also contribute. A molecule of critical impor-
tance in the pathology of sepsis is endothelin-1 
(ET-1; for reviews see references   3  –  5  ). ET-1 
is a highly potent blood pressure  –  regulating 
peptide. Under physiological conditions, ET-1 
is produced primarily by endothelial cells, and 
it is mostly secreted toward the abluminal side 
of the vessel wall, where it regulates the blood 
pressure via contraction of smooth muscle cells 
(for review see reference   6  ) (  7  ). Cell types other 
than endothelium, notably monocytes and tissue 
macrophages (  8  ), cardiomyocytes, tracheal epi-
thelium, and kidney and liver cells, are additional 
sources of ET-1 (for review see reference   4  ). 
During sepsis, ET-1 production is rapidly stim-
ulated by infl  ammatory mediators, including 
TNF, IL1    , and TGF  ß   (  4, 9  ). A link between 
mast cells and ET has been found. Mast cells 
express ET receptors, and binding of ET-1 to 
mast cells induces potent degranulation and 
release of mast cell granule content (  10, 11  ). 
This release protects normal mice, but not mast 
cell  –  defi  cient mice, from the lethal eff  ects of 
intraperitoneal injection of ET-1, possibly con-
necting the mast cell  –  dependent survival of 
peritoneal sepsis with ET-1 (  11  ). Direct activa-
tion of mast cells by ET-1 is important in this 
process because ET receptor (ET  A  ) expression 
on mast cells contributes to protection (  11  ). 
Because large amounts of ET-1 were applied 
in these studies, the physiological or pathologi-
cal relevance for the   “  mast cell  –  ET link  ”   is less 
clear. However, mast cells are also essential for 
survival of mice challenged with snake venom 
sarafotoxin 6b (S6b) (  12  ), which is a peptide 
homologous to ET-1. The function of mast 
cells in antitoxin protection is thus a novel aspect 
of innate immunity. 
  Peritoneal mast cells produce a multitude of 
granule proteases, which include one carboxy-
peptidase (mast cell carboxypeptidase A [Mc-cpa; 
also termed Cpa3]), chymases (mast cell protease 4 
CORRESPONDENCE  
 H.R.  Rodewald: 
 hans-reimer.rodewald@
uni-ulm.de
  Abbreviations used: ET, endo-
thelin; Mc-cpa, mast cell car-
boxypeptidase A; Mcp, mast cell 
protease; PEC, peritoneal exu-
date cell; S6b, sarafotoxin 6b. 
  L.A. Schneider, S.M. Schlenner, and T.B. Feyerabend contri-
buted equally to this paper.   
  Molecular mechanism of mast cell  –  mediated 
innate defense against endothelin and snake 
venom sarafotoxin 
  Lars A. Schneider,  1   Susan M. Schlenner,  1   Thorsten B. Feyerabend,  1   
Markus Wunderlin,  2   and Hans-Reimer Rodewald  1   
  1  Institute for Immunology,   2  Section for Mass Spectrometry, Institute for Organic Chemistry II, University of Ulm, 
D-89081 Ulm, Germany   
  Mast cells are protective against snake venom sarafotoxins that belong to the endothelin 
(ET) peptide family. The molecular mechanism underlying this recently recognized innate 
defense pathway is unknown, but secretory granule proteases have been invoked. To spe-
cifi  cally disrupt a single protease function without affecting expression of other proteases, 
we have generated a mouse mutant selectively lacking mast cell carboxypeptidase A (Mc-cpa) 
activity. Using this mutant, we have now identifi  ed Mc-cpa as the essential protective 
mast cell enzyme. Mass spectrometry of peptide substrates after cleavage by normal or 
mutant mast cells showed that removal of a single amino acid, the C-terminal tryptophan, 
from ET and sarafotoxin by Mc-cpa is the principle molecular mechanism underlying this 
very rapid mast cell response. Mast cell proteases can also cleave ET and sarafotoxin inter-
nally, but such   “  nicking  ”   is not protective because intramolecular disulfi  de bridges maintain 
peptide function. We conclude that mast cells attack ET and sarafotoxin exactly at the 
structure required for toxicity, and hence sarafotoxins could not   “  evade  ”   Mc-cpa  ’  s sub-
strate specifi  city without loss of toxicity. 2630 IN VIVO FUNCTION OF MAST CELL CARBOXYPEPTIDASE A | Schneider et al.
[Mcp-4] and Mcp-5), and tryptases (Mcp-6 and -7; for reviews 
see references   13  –  15  ). Although these enzymes were identifi  ed 
many years ago, and studied extensively in vitro, information 
about their in vivo functions is scarce. A major hurdle to un-
cover the functions of Mcps has been the diffi   culty to identify 
relevant in vivo substrates. This problem can now be addressed 
in mutant mice for  Mc-cpa   ( 16  ),  Mcp-4   ( 17  ), and  Mcp-5   ( 18  ) genes. 
Resistance of   Mcp-4      /        mice to ET-1/S6b excludes an essential 
protective function of this enzyme (  12  ). Mc-cpa (  19  ), which 
is a mast cell  –  specifi  c enzyme related to pancreatic carboxy-
peptidases, preferentially cleaves C-terminal aromatic amino 
acids. Mc-cpa is the only mast cell enzyme with carboxy-
peptidase activity, but mast cells lacking Mc-cpa develop in 
normal numbers, and are fully competent in degranulation, 
histamine release, and passive cutaneous anaphylaxis (  16  ). 
  Mcps are assembled in conjunction with proteoglycans 
during their synthesis in the secretory pathway (for review see 
reference   20  ).   Mc-cpa      /        mast cells concomitantly lack Mc-cpa 
and Mcp-5, despite normal expression of   Mcp-5   mRNA (  16  ), 
and Mc-cpa is absent in   Mcp-5      /        mast cells (  18  ). This implies 
that  Mc-cpa      /        and  Mcp-5      /        mice are each functionally double-
defi  cient for Mc-cpa and Mcp-5, and limits conclusions about 
the functional roles of each enzyme. 
  We sought to identify the mast cell enzyme that is re-
quired for degradation of ET-1 and S6b in vivo. To analyze 
the specifi  c role of Mc-cpa, we generated a novel mouse mu-
tant in which the wild-type   Mc-cpa   gene (  21  ) was mutated to 
a   Mc-cpa   allele (  Mc-cpa  Y356L,E378A    ) bearing two amino acid ex-
changes designed to render Mc-cpa catalytically inactive. We 
show here that homozygous mutants (termed   Mc-cpa  Y356L,E378A     
mice) are, indeed, selectively defi  cient for Mc-cpa enzyme 
activity. Interestingly, loss of this enzyme function renders 
mice susceptible to ET-1 and S6b. Moreover, by combining 
the genetic defect of   Mc-cpa  Y356L,E378A     mice with mass spectro-
metric analyses of the substrates, we uncover the molecular 
basis for this mast cell  –  mediated defense pathway protecting 
against ET-related toxins. 
  Figure 1. Protein expression, carboxypeptidase activity, and ET-1  –
  induced degranulation in mutant mast cells. (A) Lysates of purifi  ed 
peritoneal mast cells from   Mc-cpa  /    (lanes  1 – 4),   Mc-cpa  /      (lane 5), 
  Mc-cpa  Y356L,E378A    (lane 6), and   Mc-cpa    /      (lane 7) mice were analyzed by 
Western blotting for Mc-cpa (top), Mcp-5 (middle), and actin (bottom) 
expression.   Mc-cpa  /    cell lysates were titrated to estimate the level of 
Mc-cpa expression in   Mc-cpa  Y356L,E378A    mice. 100% in lane 1 corresponds 
to 14,000 purifi  ed peritoneal mast cells. Densitometric measurements of 
actin expression showed 637, 222, 69, and 46 arbitrary units in lanes 1  –  4, 
respectively, and 622, 283, and 601 in lanes 5  –  7, respectively. Measure-
ments for Mc-cpa expression showed 592, 303, 130, and 70 arbitrary 
units in lanes 1  –  4, respectively, and 401, 270, and     1 in lanes 5  –  7, re-
spectively. Based on these values, we estimate that   Mc-cpa  Y356L,E378A    mast 
cells expressed     80% of the Mc-cpa amount expressed in normal mast cells. 
(B) Lysates of 10,000 peritoneal mast cells from   Mc-cpa  /    (   ),   Mc-
cpa    /      (    ), and   Mc-cpa  Y356L,E378A    (    ) mice, and the blank (without cells) 
control (     ) were analyzed for carboxypeptidase activity by test substrate 
( 45 ).  Both   Mc-cpa    /      and   Mc-cpa  Y356L,E378A    mast cells lacked Mc-cpa ac-
tivity. (C) Mast cell degranulation in response to ET-1 in vitro. PECs from 
  Mc-cpa  /  ,   Mc-cpa    /     , and   Kit  W/Wv    mice were left without stimulus 
(white bars), treated with ET-1 (black bars), or treated with ionomycin 
(gray bars). Supernatants were analyzed for    -hexosaminidase  release 
as a measure for degranulation by colorimetric assay (  16  ). The release is 
mast cell specifi  c, as shown by the absence of    -hexosaminidase  release 
in PECs from   Kit  W/Wv    mice. Data summarize the mean  one SD for three 
(  Mc-cpa  /    and   Mc-cpa    /     ) and two (  Kit  W/Wv   ) independent experiments. 
Release was signifi  cantly different comparing unstimulated versus ET-1  –
 stimulated   Mc-cpa  /    (P   0.046) and unstimulated versus ET-1  –  stimu-
lated   Mc-cpa    /      (P   0.001) mast cells, indicating specifi  c degranulation 
of both genotypes by ET-1. In both genotypes, stimulations by ET-1 and 
ionomycin were not signifi  cantly different. P  0.5 for   Mc-cpa  /    and 
P  0.1 for   Mc-cpa   − / −   .   
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cells (unpublished data), which is consistent with the require-
ment for ET  A   expression for ET-1  –  induced degranulation of 
peritoneal mast cells (  11  ). Next, ET-1  –  induced degranulation, 
which is measured by release of     -hexosaminidase, was ana-
lyzed in mast cell  –  containing peritoneal exudate cells (PECs). 
With the exception of mast cell  –  defi  cient   Kit  W/Wv     mice (  26  ), 
numbers of peritoneal mast cells were comparable in all geno-
types analyzed (unpublished data). Relative to maximal signal-
ing by ionomycin, ET-1 stimulated strong degranulation in 
mast cell  –  containing PECs from   Mc-cpa  /     and   Mc-cpa      /       , but 
not in mast cell  –  defi  cient PECs from   Kit  W/Wv     mice (  Fig. 1 C  ). 
Hence, ET-1 specifi  cally stimulated mast cells for degranula-
tion among PECs, and loss of Mc-cpa and Mcp-5 did not im-
pair ET-1  –  stimulated granule release in mast cells. 
  Susceptibility of Mcp mouse mutants to ET-1 
  ET-1, which is the strongest endogenous blood pressure  – 
regulating peptide, has been implicated in many pathological 
    RESULTS   
  Protease expression and function in   Mc-cpa      /        and 
  Mc-cpa  Y356L,E378A     mast cells 
    Mc-cpa    –  null (  Mc-cpa      /       ) mast cells lack Mc-cpa protein (  Fig. 
1 A , lane 7) and the corresponding enzyme activity on a carboxy-
peptidase test substrate (  Fig. 1 B  ).     Mc-cpa      /        mast cells are also 
devoid of Mcp-5 protein ( Fig. 1 A , lane 7), although the  Mcp-5   
gene is functional and   Mcp-5   mRNA is expressed at normal 
levels (  16  ). Other connective tissue Mcps, notably chymase 
Mcp-4 ( 22  ) and tryptase Mcp-6 ( 15  ), are expressed in  Mc-cpa      /        
mast cells (  16  ). It is likely that Mc-cpa and Mcp-5 are co-
packaged during synthesis and sorting into secretory granules, 
but the mechanism for the failure to express Mcp-5 in the ab-
sence of Mc-cpa ( 16  ), or Mc-cpa in the absence of Mcp-5 ( 18  ), 
remains to be determined. 
  To uncover the functions of Mc-cpa independently of 
Mcp-5, we generated a second mouse mutant in which Mc-cpa 
protein expression was permissive, but in this case the enzyme 
was altered with the aim to ablate its catalytic activity. To this 
end, we mutated by homologous recombination in embry-
onic stem (ES) cells the   Mc-cpa   gene to encode two amino 
acid changes. Residues Y356 and E378 (counting from the 
ATG of the   Mc-cpa   gene), correspond to Y248 and E270 
in mature pancreatic carboxypeptidase, which is an enzyme 
homol  ogous to Mc-cpa (  23  ). In pancreatic carboxypepti-
dase, these amino acids are crucial for ligand binding and hy-
drolysis of substrate peptide bonds (  24, 25  ). Therefore, we 
mutated Y356 to L356 (termed Y356L) and E378 to A378 
(termed E378A). After germline transmission, homozygous 
  Mc-cpa  Y356L,E378A/Y356L,E378A     mutants (termed   Mc-cpa  Y356L,E378A     
mice) were bred. Details of the generation and analyses of this 
mutant will be reported in future studies. 
  In contrast to   Mc-cpa      /        mast cells (  Fig. 1 A  , lane 7), 
  Mc-cpa  Y356L,E378A     mast cells (  Fig. 1 A  , lane 6) expressed Mc-cpa 
and Mcp-5 protein. Titrated Western blots showed that 
  Mc-cpa  Y356L,E378A     mast cells expressed     80% of the amount of 
Mc-cpa protein compared with wild-type mast cells ( Fig. 1 A ). 
To exclude a dose eff  ect of reduced Mc-cpa expression in 
  Mc-cpa  Y356L,E378A     mast cells, we compared, where appropriate, 
heterozygous (  Mc-cpa  /       ) mice to   Mc-cpa  Y356L,E378A     mice. To 
test whether the introduced mutations ablated catalytic acti-
vity, enzyme function of  Mc-cpa  Y356L,E378A     mast cells was analyzed 
in vitro (  Fig. 1 B  ). Titration experiments showed that Mc-cpa 
enzyme activity was detectable in as few as 1,000   Mc-cpa  +/+     
mast cells, but undetectable in 20,000   Mc-cpa  Y356L,E378A     mast 
cells (not depicted), the highest cell number tested, and equiv-
alent to approximately one half of the total mast cell number 
present in one peritoneal cavity. Hence,   Mc-cpa  Y356L,E378A     mast 
cells expressed Mc-cpa protein lacking enzyme activity, and 
this was suffi   cient for Mcp-5 expression. 
  Mast cells express ET-1 receptors on their surface, and 
binding of ET-1 to ET-1 receptors is a potent stimulus for re-
lease of secretory granules (  10, 11  ). Using RT-PCR, we com-
pared the expression of two ET-1 receptors, the ET  A   and ET  B  , 
in purifi  ed peritoneal mast cells. ET  A   is the receptor type that is 
predominantly, if not exclusively, expressed on peritoneal mast 
  Figure 2. Susceptibility of     Mc-cpa      /                and     Mc-cpa      Y356L,E378A          mutant 
mice to ET-1. ET-1 was injected intraperitoneally into   Mc-cpa  /    (A),   Kit  W/Wv   
(B),   Mc-cpa    /      (C),   Mc-cpa  /      (D), and   Mc-cpa  Y356L,E378A    (E) mice, and the 
body temperature was tracked by rectal measurements at the indicated 
time points. Summarized total numbers of dead per injected mice are in-
dicated for each genotype. For clarity, the temperature kinetic is shown for 
representative mice.   Mc-cpa  /    and   Mc-cpa  /      showed a mild and tran-
sient temperature drop (A and D), whereas mast cell  –  defi  cient   Kit  W/Wv    (B), 
and mice lacking Mc-cpa and Mcp-5 (  Mc-cpa    /     ; C) succumbed to ET-1 
injection within 60 min. Mice lacking only catalytically active Mc-cpa 
(  Mc-cpa  Y356L,E378A   ; E) were also largely susceptible to ET-1, but the kinetic of 
the temperature drop was delayed compared with   Kit  W/Wv    or   Mc-cpa    /      mice.   2632 IN VIVO FUNCTION OF MAST CELL CARBOXYPEPTIDASE A | Schneider et al.
processes, including shock and sepsis (for reviews see references 
  6, 7  ). In an in vivo model of the pathological eff  ects of ET-1, 
intraperitoneal injection of 3     g ET-1 per mouse caused a 
rapid drop in body temperature and the death of two thirds of 
  Kit  W/Wv    , but not wild-type, mice (  11  ). In our hands, injection 
of 7.5     g ET-1 into mast cell  –  positive   Kit  /     mice (designated 
as   Mc-cpa  /     mice in   Fig. 2 A  ) showed a transient temperature 
drop, and 14/15 mice fully recovered ( Fig. 2 A ).   In contrast, the 
same dose caused a massive temperature drop within 20 min, 
and the death of 9/9  Kit  W/Wv     mice by 60 min ( Fig. 2 B ). Hence, 
this dose was used for all subsequent experiments. 
  To analyze whether Mc-cpa and/or Mcp-5 are involved in 
protection against ET-1,   Mc-cpa      /        mice were challenged by 
ET-1 (  Fig. 2 C  ). Similar to mast cell  –  defi  cient mice (  Fig. 2 B  ), 
15/16   Mc-cpa      /        mice succumbed to ET-1 injection. Although 
experiments using   Kit  W/Wv     mice underpin the requirement for 
mast cells for protection (  11  ), analyses of   Mc-cpa      /        mice, which 
have normal numbers of mast cells (  16  ), identify Mc-cpa and/or 
Mcp-5 as essential components of this defense pathway. Next, 
we determined by injection of ET-1 into   Mc-cpa  Y356L,E378A     mice 
whether Mc-cpa enzyme activity was required for protection 
against ET-1  –  induced lethality.   Mc-cpa  /     (not depicted) and 
hetero  zygous (  Mc-cpa  /       ) mice were injected in parallel (  Fig. 
2 D ).  Mc-cpa  /        controls were included because  Mc-cpa  Y356L,E378A     
mice expressed     100% of the Mc-cpa found in normal mast 
cells (  Fig. 1 A  ).   Mc-cpa  /        mice were protected, which implies 
that a reduction in protease expression does not impair the de-
fense against the applied dose of ET-1 (  Fig. 2 D  ). Interestingly, 
  Mc-cpa  Y356L,E378A     mice were largely susceptible to ET-1 (  Fig. 
2 E ). However, when compared with  Mc-cpa      /        mice ( Fig. 2 C ), 
the kinetic of the temperature drop was delayed, i.e., 8/21 mice 
survived beyond 60 min, and another 2/21 survived indefi  nitely. 
Nevertheless,   Mc-cpa  Y356L,E378A     mice were clearly susceptible to 
ET-1, which demonstrates a nonredundant role for Mc-cpa, but 
not Mcp-5, in resistance to ET-1. 
  Mast cell  –  mediated degradation of ET-1 
  To address a mechanistic link between mast cells and sur-
vival of the mice in response to exogenously applied ET-1, 
  Figure 3. Degradation of ET-1 by mast cells. (A) ELISA measurements 
of   “  residual  ”   ET-1 after incubation of ET-1 with no cells (open bar), or 
with PECs from   Mc-cpa  /    (solid bar),   Mc-cpa    /      (striped bar), or   Kit  W/Wv   
(shaded bar) mice. Mast cell  –  containing PECs from   Mc-cpa  /    (P   0.030 
[signifi  cant] comparing   Mc-cpa  /    versus   Kit  W/Wv    mice), and   Mc-cpa    /     
(P  0.037 [signifi  cant] comparing   Mc-cpa    /      versus   Kit  W/Wv    mice)  mice 
abolished ET-1 reactivity by ELISA, suggesting that ET-1 was degraded re-
gardless (P  0.78 [not signifi  cant] comparing   Mc-cpa  /    vs.   Mc-cpa    /    ) 
of the mast cell genotype. Data summarize the mean ± one standard 
deviation for three independent experiments. (B  –  F) Mass spectrometric 
analysis of ET-1 degradation (left), and schematic depiction of substrate 
products (right). ET-1 was left untreated (B) or incubated with ionomycin-
stimulated purifi  ed peritoneal mast cells from   Mc-cpa  /    (C),   Mc-cpa    /     
(D), or   Mc-cpa  Y356L,E378A    (E and F) mice. C-terminal degradation, evident by 
the appearance of ET-1 fragments corresponding to the molecular masses 
of 1  –  19 and 1  –  20, was mediated by   Mc-cpa  /    (C), but not by   Mc-cpa    /     
(D) or   Mc-cpa  Y356L,E378A    (E), mast cells. However, after incubation of ET-1 
with   Mc-cpa    /      (D) or   Mc-cpa  Y356L,E378A    (E) mast cells, the molecular mass 
increased from 2,492 (ET-1; B) to 2,510 daltons (ET-1 plus water; D and E). 
Hydrolysis of ET-1 was demonstrated after reduction of the samples by 
the disappearance of the ET-1 1  –  21 peak, and the appearance of new frag-
ments with molecular masses of 1,639 and 1,786 daltons (see Materials 
and methods) corresponding to ET-1 1  –  13 and 1  –  14, respectively (F). 
Data are representative of three independent experiments.     
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one H  2  O = 2,510 daltons), which pointed at hydrolysis of 
one peptide bond within the ET-1 molecule. ET-1 harbors 
two intramolecular disulfi  de bridges linking the cysteine in 
position 1 with that in position 15, and the cysteines in po-
sitions 3 and 11 (  27  ). In the absence of C-terminal degrada-
tion, the overall maintained length of the peptide could mask 
internal cleavage of ET-1 between the disulfi  de bridges by a 
mast cell  –  derived endopeptidase. To address this possibility, 
ET-1 was incubated with   Mc-cpa  Y356L,E378A     mast cells, and half 
of the supernatant was kept under nonreducing conditions 
in which ET-1 remained full length (  Fig. 3 E  ). The second 
half was reduced to open the disulfi  de bridges. Under reduc-
ing conditions, ET-1 (  1  –  21  ) disappeared, and shorter peptide 
fragments became apparent (  Fig. 3 F  ), which is consistent 
with an ET-1 cleavage at positions 13 and 14, i.e., within 
the two cysteines in positions 11 and 15. Thus, mast cell 
products attack ET-1 internally, causing a nick in the pep-
tide that could only be revealed under reducing conditions. 
This internal nicking was not mediated by Mcp-5 because 
the same pattern of degradation products was generated by 
  Mc-cpa      /        mast cells lacking both Mc-cpa and Mcp-5. 
  These data strongly suggested that the Mc-cpa  –  catalyzed 
removal of a single amino acid (tryptophan) from the C ter-
minus of ET-1 was necessary and suffi   cient for the mast cell  –
  mediated inactivation of ET-1. To prove that C-terminal 
de  gradation of ET-1 was suffi   cient for protection, synthetic 
peptides corresponding to full-length ET-1 (1-21) or C-
terminally shorter peptides were injected into mast cell  –  defi  -
cient   Kit  W/Wv     mice (  Fig. 4  ).   Of these, only full-length ET-1 
(  Fig. 4 A  ), but neither the 1  –  20 (  Fig. 4 B  ), nor the 1  –  19 
peritoneal mast cells were incubated with ET-1 in vitro. 
Initially, we measured ET-1 degradation by an ET-1  –  specifi  c 
ELISA. This assay has previously been reported to measure 
mast cell  –  mediated degradation of ET-1, and to reveal the 
mechanism behind how mast cells limit ET-1 toxicity (  11  ). 
ET-1 was incubated for 60 min with PECs from   Mc-cpa  /    , 
  Mc-cpa      /       , or   Kit  W/Wv     mice (  Fig. 3 A  ).   Compared with input, 
the amount of ET-1 after incubation with   Mc-cpa  /     PEC 
was reduced by   	  90%. Surprisingly, a similarly strong re-
duction in ELISA-reactive ET-1 was found after incubation 
with   Mc-cpa      /        PECs. Degradation of ET-1 was mostly mast 
cell  –  mediated, as shown by the inability of   Kit  W/Wv     PECs, 
which lack mast cells, to substantially reduce the amount of 
ET-1. These data suggested that not only normal mast cells 
but also mast cells lacking Mc-cpa and Mcp-5 proteins could 
degrade ET-1, a notion that is not easily reconciled with the 
observation that   Mc-cpa  /     mice were protected (  Fig. 2 A  ), 
whereas   Mc-cpa      /        mice were fully susceptible (  Fig. 2 C  ) 
to ET-1. This discrepancy implied that the loss of ELISA-
reactivity did not indicate whether or not ET-1 remained 
biologically active. 
  It was, therefore, of interest to obtain more direct data on 
mast cell  –  mediated ET-1 degradation to correlate specifi  c degra-
dation products with survival. To this end, ET-1 was incubated 
with mast cells of diff  erent genotypes, and the products were 
analyzed by mass spectrometry (  Fig. 3, B-F  ). Purifi  ed perito-
neal mast cells from   Mc-cpa  /    ,   Mc-cpa      /       , or   Mc-cpa  Y356L,E378A     
mice were incubated in the presence of ET-1 together with 
ionomycin for maximal stimulation. The resulting ET-1 frag-
ments were measured by mass spectrometry. Synthetic peptides 
corresponding to ET-1 (1  –  21;   Fig. 3 B  ), or peptides lacking 
one (1  –  20) or two (1  –  19) amino acids at the C terminus (not 
depicted) were measured separately, as standards. 
  In the presence of   Mc-cpa  /     mast cells, most ET-1 (1  –  21) 
was converted into shorter fragments with masses of 1  –  20 
and 1  –  19 (  Fig. 3 C  ). C-terminal degradation products were 
not generated by   Mc-cpa      /        mast cells (  Fig. 3 D  ). Thus, mast 
cells can degrade ET-1 at the C terminus, and this degrada-
tion requires expression of Mc-cpa or Mcp-5. To directly an-
alyze the role of Mc-cpa in this process, ET-1 was incubated 
with   Mc-cpa  Y356L,E378A     mast cells (  Fig. 3 E  ). Interestingly, 
ET-1 (1  –  21) was also maintained in the presence of these 
mutant mast cells lacking only catalytically active Mc-cpa. 
These experiments unequivocally identify Mc-cpa as the non-
redundant enzyme required for removal of C-terminal amino 
acids from ET-1. 
  ET-1 can also be cleaved at multiple positions by endo-
peptidases (  27  ). Along this line, Mcps other than Mc-cpa, 
notably chymases (  11, 28  ), were reported to contribute to 
ET-1 degradation, and cleavage by chymases has, in fact, been 
proposed as the protective mechanism (  11  ) (for review see 
reference   29  ). Mast cells from   Mc-cpa      /        and   Mc-cpa  Y356L,E378A     
mice could not degrade the C terminus of ET-1, but we no-
ticed a shift in the molecular mass of ET-1 from 2,492 (ET-1) 
to 2,510 daltons (  Fig. 3, D and E  ). This increase in molecular 
weight suggested addition of a water molecule (ET-1 plus 
  Figure 4. Removal of tryptophan from the C terminus renders ET-1 
nontoxic for mast cell  –  defi  cient mice. Synthetic peptides of ET-1 
(1  –  21; A) or of ET-1 minus tryptophan in position 21 (1  –  20; B) were injected 
intraperitoneally into mast cell  –  defi  cient   Kit  W/Wv    mice, and the body 
temperature was followed by rectal measurements at indicated time 
points. Mast cell  –  defi  cient   Kit  W/Wv    mice were resistant to ET-1 (1  –  20), 
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(not depicted) amino acid long peptides induced a tempera-
ture drop or lethality in   Kit  W/Wv     mice. 
  Collectively,   Mc-cpa  /    , but not   Mc-cpa  Y356L,E378A    , mast 
cells degrade the C terminus of ET-1, and this Mc-cpa  – 
mediated C-terminal shortening is highly protective because 
ET-1 (1–20) was not toxic in vivo (  Fig. 4 B  ). Moreover, 
Mcps other than Mc-cpa and Mcp-5 can nick internal pep-
tide bonds between cysteines 11 and 15 in ET-1. Apparently, 
the ELISA detects a conformation-dependent epitope that 
is missing in nicked ET-1. In contrast, in vivo experiments 
demonstrated that such heterodimers of internally cleaved, 
but   “  full-length  ”   ET-1 remained lethal in   Mc-cpa      /        and 
  Mc-cpa  Y356L,E378A     mice (  Fig. 2  ). 
  Catalytic activity of Mc-cpa is essential to protect against 
snake venom sarafotoxin 
  Snake venom sarafotoxins share signifi  cant amino acid sequence 
similarity with endogenous ET-1 ( 27, 30 ). This sequence homo-
logy appears to be immunologically relevant because mast cells 
can enhance resistance not only to ET-1 but also to snake venom 
sarafotoxins (  12  ). The molecular mechanism under  lying 
the mast cell  –  mediated degradation of sarafotoxins has not 
been fully uncovered. Given the similarities in sequence and 
structure involving two disulfi  de bridges, it appears likely that 
the mechanisms of ET and sarafotoxin degradation are similar, 
if not identical. However, the specifi  c role of Mc-cpa could 
not easily be addressed up to now because ablation of Mc-cpa 
expression by gene targeting, as in   Mc-cpa      /        mice (  16  ), or by 
RNA interference (RNAi), as in   Mc-cpa  /     BM-derived mast 
cells transplanted into mast cell  –  defi  cient mice (  12  ), inevitably 
also lead to abrogation of Mcp-5 expression (see Introduction 
and Fig. 1 A) (  12, 16  ). 
  To address whether Mc-cpa or Mcp-5 are involved in the 
resistance against S6b, which is the most toxic representative 
of this group of snake venom peptides, the diff  erent   Mc-cpa   
mouse genotypes (  Mc-cpa  /    ,   Mc-cpa  /       ,   Mc-cpa      /       , and   Mc-
cpa  Y356L,E378A    ), as well as   Kit  W/Wv     mice, were injected with 7.7     g 
S6b (  Fig. 5  ).     Mc-cpa  /     and   Mc-cpa  /        mice were protected 
(  Fig. 5 A  ), but mast cell  –  defi  cient   Kit  W/Wv     mice were not (  Fig. 
5 B  ), thereby confi  rming a crucial role of mast cells in the 
protection against S6b in vivo (  12  ). Mice lacking Mc-cpa and 
Mcp-5 (  Mc-cpa    −  /  −     ) showed a rapid temperature drop similar to 
  Kit  W/Wv    , and all   Mc-cpa    −  /  −      mice succumbed to S6b injection 
(  Fig. 5 C  ). Interestingly,   Mc-cpa  Y356L,E378A     mice were also fully 
susceptible to S6b (  Fig. 5 D  ). In contrast to the delayed ET-1  – 
induced lethality of   Mc-cpa  Y356L,E378A     mice when compared 
with   Kit  W/Wv     or to   Mc-cpa    −  /  −      mice (  Fig. 2  ),   Mc-cpa  Y356L,E378A     
mice were equally vulnerable to S6b as   Kit  W/Wv     or   Mc-cpa      /        
mice (  Fig. 5  ). These experiments establish an essential role for 
Mc-cpa in the mast cell defense against S6b. 
  Mast cell  –  mediated, C-terminal degradation of S6b 
  S6b degradation products that were generated by incubation 
of S6b with ionomycin-stimulated peritoneal mast cells from   
Mc-cpa  /    ,  Mc-cpa      /       , or  Mc-cpa  Y356L,E378A     mice were analyzed by 
mass spectrometry (  Fig. 6  ).   We observed C-terminal shortening 
  Figure 5. Susceptibility of     Mc-cpa     mutants to S6b. The S6b was 
injected intraperitoneally into   Mc-cpa  /    (A),   Mc-cpa  /      (only  numbers 
shown in A),   Kit  W/Wv    (B),   Mc-cpa    /      (C), and   Mc-cpa  Y356L,E378A    (D) mice, and 
the body temperature was followed by rectal measurements at the indicated 
time points. Summarized total numbers of dead per injected mice are indi-
cated for each genotype. The temperature kinetic of   Mc-cpa  /      mice  (not 
depicted) was similar to the one from   Mc-cpa  /    mice. All strains except for 
  Mc-cpa  /    and   Mc-cpa  /      mice succumbed to S6b injection within 60 min. 
The full susceptibility of   Mc-cpa  Y356L,E378A    mice demonstrates the essential 
role of Mc-cpa enzyme activity for survival of snake venom S6b.    JEM VOL. 204, October 29, 2007 
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C terminus. Hence, Mc-cpa activity is not only essential for 
C-terminal degradation of ET-1 but also of S6b. 
  The sequences of ET-1 and S6b are identical in 14/21 
amino acids, and S6b, like ET-1, contains two disulfi  de bridges. 
of S6b (  Fig. 6 A  ) by   Mc-cpa  /     mast cells (  Fig. 6 B  ). Consistent 
with the susceptibility of   Mc-cpa      /        and   Mc-cpa  Y356L,E378A     mice 
to S6b (  Fig. 5  ), mast cells from   Mc-cpa      /        (not depicted) and 
  Mc-cpa  Y356L,E378A     (  Fig. 6 C  ) mice failed to degrade S6b at the 
  Figure 6. Degradation of S6b by mast cells. (A  –  D) Mass spectrometric analyses (left side) of degradation products of S6b. Resulting peptides are 
schematically depicted on the right side. S6b was left untreated (A) or incubated with ionomycin-stimulated purifi  ed mast cells from   Mc-cpa  /    (B)  or 
  Mc-cpa  Y356L,E378A    (C and D) mice. C-terminal degradation, which is evident from the appearance of fragments corresponding to the molecular mass of S6b 
(1  –  19; 2,266 daltons), was mediated by   Mc-cpa  /    (B), but not by   Mc-cpa  Y356L,E378A    (C) mast cells. The peak marked by the asterisk in B does not corre-
spond to a fragment of S6b, and it was not observed in a second experiment. The molecular mass of S6b (1  –  21) increased after incubation with 
  Mc-cpa  Y356L,E378A    mast cells from 2,565 (1  –  21; A) to 2,583 daltons (S6b 1  –  21 plus water; C). This indicated hydrolysis of S6b, which was proven after reduc-
tion of the samples by the disappearance of the S6b 1  –  21 peak, and the appearance of residual fragments with molecular masses of 1,710 and 1,858 
daltons (see Materials and methods) corresponding to S6b 1  –  13 and 1  –  14, respectively (D). Data are representative for two independent experiments.     2636 IN VIVO FUNCTION OF MAST CELL CARBOXYPEPTIDASE A | Schneider et al.
The homology is even higher between positions 8 and 21 
(identity in 11/14 amino acids). In ET-1, the degradation 
products were consistent with endopeptidase cleavage at 
position 13 or 14. Tyrosine (  13  ) and phenylalanine (  14  ) are 
conserved in ET-1 and S6b. To determine whether mast cell 
products also cleaved S6b internally, S6b was incubated with 
  Mc-cpa  Y356L,E378A     mast cells, and the samples were analyzed 
with and without reduction by mass spectrometry. Without 
reduction, addition of a water molecule, which is indicative 
of hydrolysis of as single-peptide bond, was revealed by the 
corresponding mass increase (  Fig. 6 C  ). After reduction, S6b 
(  1  –  21  ) disappeared, and reaction products consistent with 
the masses of 1  –  13 and 1  –  14 fragments of S6b (  Fig. 6 D  ) 
pointed at an identical endopeptidase digestion pattern com-
paring ET-1 and S6b. The identical pattern of reduced S6b 
reaction products occurred when   Mc-cpa      /        mast cells were 
incubated with S6b (not depicted). Thus, as for ET-1, the 
internal cleavage was not mediated by Mcp-5, and internally 
nicked, C-terminally intact S6b remained lethal. 
    DISCUSSION   
  In contrast to the notoriously harmful role of mast cells in 
allergic disease, new mast cell functions in immunity are 
emerging. Mast cell properties such as protection against 
the lethal toxicity of snake venom sarafotoxins raise ques-
tions as to which mast cell eff  ector molecules mediate these 
innate immune responses, and by what mechanism. Mcps 
are good candidates for relevant eff  ector molecules because 
they represent major protein components in mast cell gran-
ules that are secreted during signaling-dependent degranula-
tion. However, Mcps have been commonly viewed as tissue 
damaging (  31  ). In contrast, the high degree of evolutionary 
conservation of Mcps in various species, as well as the strong 
expression of proteases, suggests positive functions. Impaired 
worm expulsion in mice lacking a mucosal Mcp, Mcp-1 (  32  ), 
is an example of a protease contributing to protection. 
  Recent reports demonstrated that mast cells must be pre-
sent in the peritoneal cavity for mice to survive a challenge 
with the blood pressure regulating peptide ET-1 (  11  ), and the 
related S6b (  12  ). Protection against these peptides is initiated 
by binding of ET or sarafotoxin to ET receptors that induce 
rapid and potent degranulation of peritoneal mast cells (  Fig. 7, 
A-C  ) (  10, 11  ).   ET  A   is the major ET receptor expressed 
on peritoneal mast cells (not depicted) (  11  ), and expression 
of ET  A   on mast cells is important, as ET  A  -defi  cient mast cells 
are nonprotective (  11  ). 
  Attempts have been made to identify the relevant eff  ec-
tor molecules. Because mast cell stimulation by ET-1 causes 
degranulation, but also the production of cytokines such as 
TNF-  
   and IL-6 (  10  ), a large number of well-known factors 
could be considered. Because ET-1 and S6b are peptides, the 
underlying mechanism could be Mcp-mediated proteolysis 
that abrogates the lethal action of ET-1 and S6b in vivo (  33  ). 
Earlier in vitro experiments showed that mast cell enzymes 
can degrade ET-1 (  28  ). Maurer et al. (  11  ) used pharmacolog-
ical protease-inhibitors to characterize the ET-1  –  degrading 
  Figure 7. Molecular mechanism of ET family peptide degradation by 
Mc-cpa. (A  –  C) ET-1 and S6b, shown here for ET-1, stimulate mast cells 
via binding to ET receptors. The receptor type most prominently expressed 
on peritoneal mast cells is ET  A .  ET A   activation leads to massive degranula-
tion, which is comparable to stimulation via ionomycin, and release of 
mast cell granule content. These early events are identical in mast cells 
from   Mc-cpa  /    (A – C;  left)  and   Mc-cpa  Y356L,E378A    (A – C;  right)  mice.  (D – H) 
Mast cells secrete a set of proteases that include one carboxypeptidase A 
(Mc-cpa) and several chymases that include Mcp-5. Mc-cpa attacks the 
C terminus of ETs, and removes amino acids in position 21 (Trp; D) and 20 
(Ile; F). These modifi  cations render ETs and related toxins biologically 
in  active by three orders of magnitude (G;   34  ), and the mice survive (H). 
  Mc-cpa  Y356L,E378A    mice, which selectively lack active Mc-cpa, are unable to 
attack the C terminus of ET-1 (I). Mast cell products (possibly Mcp-4) 
other than Mc-cpa and Mcp-5 attack ET-1 internally by hydrolysis (E and I). 
Although the molecular structure (  46  ) of position 13  –  nicked ET-1 is 
likely altered, ET-1 fragmentation is prevented by the disulfi  de bridge 
(1 to 15; E and I), and the molecules retain their toxicity (J and K), unless 
the C terminus is truncated (E).   Mc-cpa  Y356L,E378A    mutant mice are unable 
to do so, and succumb to exogenous ET-1 and related toxins, thereby 
demonstrating the essential role of Mc-cpa for this innate immune 
pathway. Whether or not Mc-cpa is also involved in the degradation of 
endogenously produced ETs remains to be investigated.     JEM VOL. 204, October 29, 2007 
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in vivo toxicity. It remains to be determined whether internal 
cleavage has absolutely no eff  ect on the biological activity of 
ET-1 in vivo. 
  The in vivo toxicity of mast cell  –  mediated degradation 
products of ET-1 is in agreement with previous structure  – 
function analyses of ETs. ETs nicked by endopeptidase main-
tains toxicity (  27  ), whereas the two C-terminal residues (Ile 
and Trp) are important for receptor binding and biological 
activity of ETs (  34, 35  ). A note of caution should be made 
regarding ELISA measurements of ET-1 degradation. This 
assay, used before to correlate in vitro degradation with 
in vivo toxicity (  11  ), was, in our hands, misleading because it 
indicated degradation even by mast cells that could not pro-
tect mice in vivo (  Fig. 2   versus   Fig. 3  ). It is possible that 
immunoreactivity in this assay was abrogated by the internal 
nicks, or by conformational changes. In any case, it may be 
prudent to consider the biological activity of ET-1 when fur-
ther studying the mast cell  –  mediated degradation of ET-1 in 
the future. 
  Collectively, we have shown that Mc-cpa is an essential 
eff  ector molecule within the   “  mast cell  –  ET link  ”   providing 
a very rapid (minutes) and life-saving response of toxin neu-
tralization in vivo. Several sites on ET-1 are attacked by mast 
cells but only the C-terminal degradation is a safeguard. It is 
remarkable that the protective Mcp, Mc-cpa,   “  targets  ”   ex-
actly that amino acid in snake venom sarafotoxin that is essen-
tial for toxicity. This substrate specifi  city of Mc-cpa, as well 
as the fast circuit composed of binding of sarafotoxin to ET 
receptors, expressed on the cell surface of mast cells, followed 
by the rapid degranulation, release of the protective enzyme, 
and cleavage of the toxin, may represent an evolutionarily 
well conserved, and hence old, function of mast cells. ET-1 
levels in plasma, liver, and peritoneal cavity rapidly rise dur-
ing experimental sepsis, such as in cecal ligation and puncture 
models (  36  –  38  ). Moreover, in human sepsis patients, high 
levels of ET-1 are correlated with morbidity and mortality 
(  4, 39  ). ET-1 is thought to be involved in the pathological 
manifestations of sepsis in many organs, including heart, lung, 
liver, kidney, and intestines (  4, 9  ). Massive local or systemic 
ET-1  –  mediated vasoconstriction (  40  ) is a major pathological 
mechanism in sepsis as shown by benefi  cial eff  ects of ET re-
ceptor antagonist treatment in models of sepsis (  41  ). The ob-
servation that mast cells are closely located, among other sites, 
to blood vessels, and present in the peritoneal cavity, suggests 
that mast cells are exposed systemically or locally to changes 
in ET-1 levels (  42  ). Mast cells are not only activated by ET-1 
via ET  A   (  10  ) but also have a potent mechanism to inactivate 
ET-1 via secretion of Mc-cpa. Hence, mast cells may play an 
important role in either promoting an infl  ammatory cascade 
in response to ET  A   stimulation by releasing mediators such 
as TNF or in dampening the deleterious pathophysiological 
eff  ects of ET-1 on the vascular system by Mc-cpa  –  mediated 
rapid cleavage of ET-1. It remains to be determined under 
which conditions of local or systemic infl  ammation the eff  ect 
of ET-1 on mast cells and the reciprocal inactivation of ET-1 
by mast cells prevail. 
Mcp, and concluded that a mast cell chymase, but not Mc-cpa, 
was responsible for ET-1 inactivation in the peritoneal cavity 
(  29  ). In contrast to these pharmacological blocking studies, 
a role for Mc-cpa in ET-1 and also S6b degradation in vivo 
was suggested in more recent experiments by the same 
group using RNA interference (RNAi) (  12  ). It must be 
pointed out that the latter experiment led to a reduction 
of Mc-cpa expression in mast cells to     20% of the wild-
type level, but also, as expected from our previous knock-
out experiments (  16  ), to the concomitant loss of Mcp-5 
expression (  12  ). This double-defi  ciency of Mc-cpa and Mcp-5 
in   Mc-cpa      /       , but also in Mc-cpa RNAi knockdown experi-
ments, precluded a defi  nitive identifi  cation of the responsible 
Mcp up to now. 
  To address the exclusive function of Mc-cpa, we gener-
ated a mouse homozygous for a mutated   Mc-cpa   allele. Based 
on data from previous structure  –  function experiments that 
addressed the catalytic mechanism in pancreatic Cpa (  24, 25  ), 
we mutated Y356 to L356 and E378 to A378. The observa-
tion that   Mc-cpa  Y356L,E378A     mast cells expressed Mc-cpa pro-
tein that lacked detectable carboxypeptidase activity (  Fig. 1  ) 
showed that pancreatic and mast cell carboxypeptidases are 
not only homologous in their amino acid sequences but that 
homologous amino acids are also functionally conserved. One 
important aspect of   Mc-cpa  Y356L,E378A     mast cells was the stoi-
chiometrically normal expression of Mcp-5 (  Fig. 1  ), which 
demonstrates a structural, rather than an enzymatic, Mc-cpa 
requirement for Mcp-5 expression. This, in turn, was a pre-
requisite to specifi  cally evaluate the function of Mc-cpa. 
  Previous experiments addressing the mast cell  –  mediated 
degradation of ET-1 led to the conclusions that chymases 
and Mc-cpa (  28  ), or chymases but not Mc-cpa (  11  ), or Mc-
cpa but not chymases (  12  ) degrade ET-1. Challenging   Mc-
cpa  Y356L,E378A     mice by ET-1 and S6b now revealed directly 
that the enzyme activity of Mc-cpa is essential for protec-
tion against ET-1 (  Fig. 2  ) and S6b (  Fig. 5  ). Identifi  cation of 
Mc-cpa as the functionally relevant enzyme also helped to clarify 
which proteolytic mechanism is protective. Combining the 
genetic defects of   Mc-cpa      /        or   Mc-cpa  Y356L,E378A     mast cells 
with mass spectrometric analyses of substrates showed two 
sites of attack. The fi  rst is C-terminal removal of one (  Fig. 
7 D  ) or two (  Fig. 7 F  ), or more (  28  ) amino acids. This step 
is exclusively catalyzed by Mc-cpa as shown by intact C ter-
mini after contact with   Mc-cpa  Y356L,E378A     mast cells (  Fig. 7 I  ). 
That this is the protective reaction was further supported by 
the lack of toxicity of synthetic ET-1 (1  –  20) in mast cell  –  de-
fi  cient mice (  Fig. 4  ). The second site of attack is internal 
cleavage at positions 13 or 14 (Fig. 7 E). This could be con-
clusively detected in the absence of C-terminal degradation, 
i.e., in the presence of mutant mast cells lacking Mc-cpa pro-
tein (  Mc-cpa      /       ; not depicted) or activity (  Mc-cpa  Y356L,E378A    ; 
  Figs. 3 F and 6 D  ) under reducing conditions. Because hy-
drolysis was seen using   Mc-cpa      /        mast cells (  Fig. 3 D  ), the 
reaction is not catalyzed by Mcp-5. The consequence of in-
ternal attack on ET-1 by mast cells remains elusive because 
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were excluded from the analysis. Changes in body temperature were fol-
lowed by periodic measurements of rectal temperature using a Qtemp 200 
(VWR International) thermometer. 
  Mass spectrometry.     15,000 PMCs (Kit    +     PEC) in 120     l acetate buff  er 
(150 mM NH  4  Ac, pH 7.4, 130 mM NaCl, and 1.4 mM CaCl  2  ) were pre-
warmed for 10 min at 37  °  C, and stimulated by the addition of 2     M iono-
mycin and 1.25     g ET-1, or by the addition of 2     M ionomycin and 1.25     g 
S6b. After incubation at 37  °  C for 60 min, the cells were pelleted at 500   g   for 
3 min and 100     l of supernatant was split into 2 50-    l aliquots. For reducing 
conditions, the sample was dried again under vacuum, resuspended in 10     l 
DTT solution (2.5 mM DTT in 10 mM NH  4  HCO  3  ), and incubated over-
night at 4  °  C. After addition of 2.5     l IAA solution (10 mM IAA in 10 mM 
NH  4  HCO  3  ), the sample was incubated for 30 min in the dark. Under re-
ducing conditions, the molecular mass of the fragments was increased by the 
binding of one IAA molecule (molecular weight, 58 daltons) to each sulfate 
group. Nonreduced and reduced samples were desalted with PerfectPure 
C18 tips (Eppendorf), eluted with 10    l acetonitril/0.1% TFA, and mixed 1:1 
with   
  -cyano-4-hydroxycinnaminic acid matrix before analysis. Mass spec-
trometry was done on a REFLEX IV MALDI-TOF mass spectrometer 
(Bruker-Daltonics). Full-length ET-1 was purchased by Sigma-Aldrich or 
custom made by Bachem (ET-1 in the length of 1  –  19, 1  –  20, and 1  –  21), and 
S6b was purchased from Alexis. 
  ET ELISA.     To measure the potential degradation of ET-1 by ELISA, mast 
cell  –  containing PECs were resuspended in 120     l Tyrode  ’  s buff  er (see Mast 
cell degranulation assay), and incubated with 1.25     g ET-1 for 30 min at 
37  °  C to stimulate degranulation, as shown in   Fig. 1 C  . At the end of the in-
cubation period that allowed mast cell products to   “  attack  ”   ET-1, cells were 
pelleted at 500   g   for 3 min at 4  °  C, and supernatants were collected. Samples 
of these supernatants were tested in the     -hexosaminidase assay to control 
for degranulation, and analyzed by ELISA for residual ET-1. The ELISA kit 
(Biomedica) was used according to the manufacturer  ’  s instructions. Serial 
dilutions of the samples were analyzed in parallel. The amount of input versus 
output ET-1 was taken as a measure for mast cell  –  mediated ET-1 degradation. 
Data were analyzed by Student  ’  s   t   test. 
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    MATERIALS AND METHODS   
  Mice and gene targeting.       WBKit  W/+    ,   C57BL/6Kit  Wv/+     mice (Japan-SLC) 
and   WBB6F1Kit  W/Wv     mice were bred as previously reported (  43  ).   Mc-cpa      /        
mice (  16  ) were backcrossed for 12 generations to the C57BL/6 strain, and 
maintained on this background.   Mc-cpa  Y356L,E378A     mice were generated by 
gene targeting (  “  knock-in  ”  ) in E14.1 ES cells (129/OlaHsd). The target-
ing construct was assembled in a pBSK-based vector bearing a loxP-fl  anked 
neomycin (  Neo  ) resistance gene and the HSV thymidine kinase gene (  TK  ; 
provided by H. Luche and H.J. Fehling, University of Ulm, Ulm, Germany). 
The NotI-linearized vector consisted, from 5     to 3    , of a 1.6-kb homologous 
  “  short arm  ”   (nucleotides 24,438 to 26,059 of the   Mc-cpa   gene, according 
to Ensembl gene number ENSMUSG00000001865), the   Neo   gene under 
the   TK   promotor in the opposite orientation to the   Mc-cpa   locus, a 5.6-kb 
homologous   “  long arm  ”   (nucleotide 26,077 to +5,141 of   Mc-cpa   gene) and 
the   TK   gene in the orientation of the   Mc-cpa   locus. The long arm harbored 
exon 11, which was mutated from tac  →  ttg (nucleotide 1,072  –  1,074, accord-
ing to National Center for Biotechnology Information Entrez mRNA num-
ber NM_007753), resulting in a substitution of tyrosine 356 to leucine, and 
from gag  →  gcg (nucleotide 1138  –  1140 [NM_007753]), resulting in a substi-
tution of glutamic acid 378 to alanine. PCR-based mutagenesis was done as 
previously described ( 44  ). Gene targeting led to insertion of the  Neo   gene into 
intron 10. Gene targeting, ES cell selection,   Neo   gene excision in ES cells, 
and the generation of chimeric mice were done as previously described (  16  ). 
All animal experiments were performed in accordance with institutional 
and government regulations and were approved by Regierungspr  ä  sidium 
T  ü  bingen, Germany. 
  Western blots.    Protease expression was analyzed as previously described ( 16  ). 
Briefl  y, proteins were separated by 11.5% SDS-PAGE, followed by blotting 
onto PVDF membranes (Millipore). Rat anti  –  mouse antisera specifi  c for 
Mc-cpa and Mcp-5 (provided by Lars Hellman, Uppsala University, Sweden) 
were used at 1:200 dilutions. Blots were developed by anti  –  rat  –  horseradish 
peroxidase (1:100,000 dilution; GE Healthcare) as the second step, followed 
by ECL substrate (Pierce Chemical Co.). Actin expression was analyzed us-
ing monoclonal mouse anti  –      -actin (clone AC-15; 1:3,000 dilution; Sigma-
Aldrich), followed by polyclonal rabbit anti  –  mouse  –   horseradish peroxidase 
(1:1,000 dilution; Dako Cytomation). 
  Mc-cpa enzyme assay.     Mast cells were lysed in PBS, 2 M NaCl, and 1% 
Triton X-100 for 15 min on ice. The lysate volume corresponding to 10,000 
cells/well was adjusted to 60     l with lysis buff  er and mixed with 40     l 
water and 20     l chromogenic substrate (1.8 mM; N-[4-methoxyphenyl-
azoformyl]-Phe-OH; Bachem). Substrate degradation was measured as the 
change over time in absorbance at OD  405   with a SpectraMax 250 (MWG 
Biotech) spectrophotometer. 
  Mast cell degranulation assay.    PECs were resuspended in 120    l Tyrode ’  s 
buff  er (10 mM Hepes, 130 mM NaCl, 5 mM KCl, 1.4 mM CaCl  2  , 1 mM 
MgCl  2  , 5.6 mM glucose, and 0.1% BSA, pH 7.4) and stimulated with either 
2     M ionomycin or 1.25     g ET-1 for 15 min at 37  °  C. The cells were 
pelleted at 500 g for 3 min before collection of the supernatants. To mea-
sure     -hexosaminidase release, 50     l of the supernatant was mixed with an 
equal volume of substrate (p-nitrophenyl-  N  -acetyl-    -  d  -glucosaminide). A 
25-mM stock of p-nitrophenyl-  N  -acetyl-    -  d  -glucosaminide in DMSO was 
diluted 1:25 in 0.1 M citrate buff  er, pH 4.5, before use. After 90 min of 
incubation at 37  °  C, the reaction was stopped by addition of 125     l of 1 M 
Tris, and the substrate conversion was measured photometrically at OD  405  . 
Data were analyzed by Student  ’  s   t   test. 
  In vivo toxicity.     Mice were injected intraperitoneally with ET-1 (7.5     g 
in 300     l/mouse; 1  –  21), ET-1 (6.9     g in 300     l/mouse; 1  –  20), or S6b 
(7.7     g in 300     l/mouse). To verify proper intraperitoneal injection, the 
injected fl  uid contained 0.1     g/ml Evans blue. At the end of the experi-
ment, the peritoneal cavity was opened in each mouse to identify free blue 
peritoneal fl  uid as an indicator of successful injection. Mice lacking this fl  uid JEM VOL. 204, October 29, 2007 
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